Benzo[a]phenoxazines: a new group of potent P-glycoprotein inhibitors
Wesolowska, O.; Molnar, J.; Westman, G.; Samuelsson, K.; Kawase, M.; Ocsovszki, I.; Motohashi, N.; Michalak, K.
In Vivo 20(1): 109-113
2006
ISSN/ISBN: 0258-851X PMID: 16433037 Document Number: 595393
The ability of fifteen novel phenoxazine derivatives (four phenoxazines and eleven benzophenoxazines which are important for MDR modulation.
Document emailed within 1 workday
Related Documents
Dal Piaz, V.; Ciciani, G.; Giovannoni, M.P. 1997: Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: a new group of potent platelet aggregation inhibitors Farmaco 52(3): 173-178Dhar, J.D.; Setty, B.S.; Duran, S.; Kapil, R.S. 1991: Biological profile of 2-[4-(2-N-piperidinoethoxy) phenyl]-3-phenyl (2H) benzo (b) pyran--a potent antiimplantation agent in rat Contraception 44(4): 461-472
Yeh, G.C.; Lopaczynska, J.; Poore, C.M.; Phang, J.M. 1992: A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells Cancer Research 52(23): 6692-6695
Dantzig, A.H.; Shepard, R.L.; Cao, J.; Law, K.L.; Ehlhardt, W.J.; Baughman, T.M.; Bumol, T.F.; Starling, J.J. 1996: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Cancer Research 56(18): 4171-4179
Parsons, W.H.; Hajdu, R.; Schoen, W.R.; Combs, P.L.; Sundelof, J.; Patchett, A.A. 1991: A new class of potent, slowly reversible dehydropeptidase inhibitors Biochemistry International 23(6): 1107-1115
Bobrowska-Hägerstrand, M.; Lillås, M.; Mrówczyñska, L.; Wróbel, A.; Shirataki, Y.; Motohashi, N.; Hägerstrand, H. 2006: Resveratrol oligomers are potent MRP1 transport inhibitors Anticancer Research 26(3a): 2081-2084
Griffin, R.J.; Pemberton, L.C.; Rhodes, D.; Bleasdale, C.; Bowman, K.; Calvert, A.H.; Curtin, N.J.; Durkacz, B.W.; Newell, D.R.; Porteous, J.K. 1995: Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP) Anti-Cancer Drug Design 10(6): 507-514
Lincoff, A.M. 2004: Glycoprotein IIb/IIIa inhibitors Journal of Invasive Cardiology 16(7 Suppl): 11s-16s
Subbarao, V.; Phillips, J.; Stouffer, G.A. 1998: Update on glycoprotein IIb/IIa inhibitors Idrugs: the Investigational Drugs Journal 1(6): 668-674
Aarthy, M.; Singh, S.Kumar. 2018: Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach Current Topics in Medicinal Chemistry 18(18): 1585-1602
Okamoto, S.; Hijikata, A.; Kinjo, K.; Kikumoto, R.; Okubo, K. 1975: A novel series of synthetic thrombin-inhibitors having extremely potent and highly selective action Kobe Journal of Medical Sciences 21(2): 43-51
Wong, P.C.; Quan, M.L.; Crain, E.J.; Watson, C.A.; Wexler, R.R.; Knabb, R.M. 2000: Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics Journal of Pharmacology and Experimental Therapeutics 292(1): 351-357
Nixon, J.S.; Bottomley, K.M.; Broadhurst, M.J.; Brown, P.A.; Johnson, W.H.; Lawton, G.; Marley, J.; Sedgwick, A.D.; Wilkinson, S.E. 1991: Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro International Journal of Tissue Reactions 13(5): 237-241
Hajdúch, M.; Havlíèek, L.; Veselý, J.; Novotný, R.; Mihál, V.; Strnad, M. 1999: Synthetic cyclin dependent kinase inhibitors. new generation of potent anti-cancer drugs Advances in Experimental Medicine and Biology 457: 341-353
Baston, E.; Klein, C.D.; Grimminger, W.; Hebecker, N.; Hartmann, R.W. 2001: Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type Anti-Cancer Drug Design 16(1): 37-47
Kapetanovic, I.M.; Kupferberg, H.J. 1984: Nafimidone, an imidazole anticonvulsant, and its metabolite as potent inhibitors of microsomal metabolism of phenytoin and carbamazepine Drug Metabolism and Disposition: the Biological Fate of Chemicals 12(5): 560-564
Sievers, E.L.; Smith, F.O.; Woods, W.G.; Lee, J.W.; Bleyer, W.A.; Willman, C.L.; Bernstein, I.D. 1995: Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group Leukemia 9(12): 2042-2048
Walsmann, P.; Markwardt, F.; Stürzebecher, J.; Wagner, G.; Wunderlich, I. 1979: Synthetic inhibitors of serine proteinases. 20. the inhibitory effect of benzo condensed lactam derivatives of benzamidine on trypsin, plasmin and thrombin Die Pharmazie 34(3): 194-195
Ghosh, S.; Narla, R.K.; Zheng, Y.; Liu, X.P.; Jun, X.; Mao, C.; Sudbeck, E.A.; Uckun, F.M. 1999: Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents Anti-Cancer Drug Design 14(5): 403-410
Corral, L.G.; Haslett, P.A.; Muller, G.W.; Chen, R.; Wong, L.M.; Ocampo, C.J.; Patterson, R.T.; Stirling, D.I.; Kaplan, G. 1999: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha Journal of Immunology 163(1): 380-386